The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Dr.Paolo Zamboni has made a huge breakthrough in Multiple Sclerosis research. Sales of Tysabri and Avonex will go down. Even the new drug, Fampridine will struggle. http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20091120/W5_liberation_091121/20091121?s_name=W5 Patients with Multiple Sclerosis and banding together to get tested and treated for Chronic Cerebral Spinal Insufficiency (CCSVI). Clinical trials already show a strong correlation between MS and CCSVI. A surgery (angioplasty or stents) on jugular veins are dramatically reducing symptoms of MS. http://ccsvivictory.club.officelive.com/ConflictsofInterest.aspxOr, www.ctv.ca Search “CCSVI”And www.ccsvivictory.club.officelive.com check “conflicts of interest” tab